Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Spatiotemporal Mapping of Immune Cell Behavior in Glioblastoma

Objectif

Immune cells, particularly cytotoxic T lymphocytes, are highly motile capable of infiltrating and eliminating tumors—a feature driving the recent revolution of immunotherapies. Yet a common barrier is the failure of T cells to infiltrate tumors, with local peritumoral and perivascular arrest as a key hurdle. Efforts to overcome this, such as decades of targeting of major tumor-supportive cytokines have yielded limited breakthroughs. A likely reason is methodological bias: most studies profile bulk tissues at single endpoints, detecting only sustained, widespread signals while overlooking the transient, localized interactions that may drive T-cell arrest.
I propose to develop spatially and temporally resolved transcriptomic technology to map immune cell interactions and behavior over time, and apply it to study immune dysfunction in glioblastoma (GBM), a lethal brain tumor. I recently developed Zman-seq, the first in vivo single-cell method to capture immune cell state transitions over time and their driving signals. Zman-seq revealed that immune reprogramming occurs rapidly within just a day after infiltration. To resolve the early local interactions driving this, we will combine spatial data with Zman-seq, and measure T-cell motility as a functional readout. First, to pinpoint the early niches, I will combine Zman-seq timestamps with spatial transcriptomics and describe how immune cells occupy cellular niches over time. Next, to study T-cell behavior within these niches, I will directly visualize T-cell motility via intravital microscopy and register in vivo tracks to ex vivo spatial transcriptomics, creating a new approach—VideoTranscriptomics. Applied in a GBM model, this will reveal the sequence of niches immune cells traverse, and pinpoint early, targetable checkpoints that drive T-cell arrest and immunotherapy resistance.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC - HORIZON ERC Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2026-STG

Voir tous les projets financés au titre de cet appel

Institution d’accueil

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Contribution nette de l'UE
€ 1 484 173,00
Adresse
IM NEUENHEIMER FELD 280
69120 Heidelberg
Allemagne
Région
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Type d’activité
Research Organisations
Liens
Coût total
€ 1 484 173,75

Bénéficiaires (1)